Scotiabank analyst Greg Harrison raised the firm’s price target on BridgeBio (BBIO) to $49 from $48 and keeps an Outperform rating on the shares. BridgeBio recently announced its European partner ...

AB-1002 is an investigational gene therapy for the treatment of adults with non-ischemic cardiomyopathy and New York Heart Association (NYHA) ...

If a language can be used to build web scrapers, it definitely needs to provide a graceful data visualization library. --- by dongdong. In the Golang ecosystem, there are not many choices for data ...

Cardiomyopathies are diseases of the heart muscle. This group of pathological conditions includes dilated cardiomyopathy, hypertrophic cardiomyopathy, restrictive cardiomyopathy, arrhythmogenic ...

Bristol-Myers Squibb's Cobenfy launch shows strong initial sales and growth potential. Learn why BMY stock is a solid ...

The week's most popular streamed songs (audio + video) on leading digital music services as compiled by Luminate. Bad Bunny Last week Weeks at no. 1 Weeks on chart B.A.Martinez Ocasio, R.Rosardo ...

Send us a tip using our anonymous form. A daily briefing on what matters in the music industry Send us a tip using our anonymous form.

The United States market has shown robust performance recently, climbing 3.0% in the last week and achieving a 25% increase over the past year, with earnings expected to grow by 15% annually.

Dr. Kilaru has has worked on more claims relating to Atrial Flutter, Arrhythmias and Cardiomyopathy than other providers in the area. At present, Dr. Kilaru has received an average rating of 4.5 ...

ESPN's MLB depth charts will be updated live every day throughout the 2025 MLB season for every trade, promotion and injury that shapes the big league roster. Keep up with the rotation ...

The decrease in mortality, morbidity were seen with trametinib for children with RASopathy-associated hypertrophic cardiomyopathy. HealthDay News — For children with severe hypertrophic cardiomyopathy ...

The United States (US) Food and Drug Administration (FDA) approved mavacamten for the treatment of obstructive hypertrophic cardiomyopathy (HCM) in 2022. However, due to left ventricular (LV) systolic ...